Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a preliminary revenue forecast for the fiscal year ending December 31, 2023. The company expects to report revenues within the range of RMB 124-126 million (USD 17.2-17.5 million), a significant increase compared to the RMB 12.8 million (USD 1.78 million) recorded in the previous year.
This substantial growth is attributed to the successful marketing approvals of their products in China during the past year. The antibiotic Xerava (eravacycline) received approval to treat complicated intra-abdominal infections (cIAI) in March and was officially launched in July. Additionally, Nefecon (sustained-release budesonide) was granted approval in Macau in October and was commercialized in the region two months later.- Flcube.com
